Ant Ryall

Finance Director and Masters Crossfitter

[Ant Ryall @AntRyall]

#gdr

[genedrive plc @genedriveplc]

Professor Bill Newman, PALOH study lead and Consultant in Genomic Medicine at MFT highlights the benefits of the Genedrive® MT-RNR1 ID Kit, one of the 1st products to be assessed by #NICE in their new EVA programme.
📢Full report next week
#GDR #NHS #POCT #pharmacogenetics

[Ant Ryall @AntRyall]

#gdr

[genedrive plc @genedriveplc]

Roll out of Genedrive® MT-RNR1 ID Kit across Greater Manchester hospitals. @HealthInnovMcr to support wider adoption of the rapid point of care test in neonatal units across the region #GDR #NHS https://t.co/QzfSkvNeKK

[Ant Ryall @AntRyall]

#gdr

[Share_Talk ™ @Share_Talk]

@genedriveplc (AIM #GDR) UK’s National Institute for Health and Care Excellence (NICE) has preliminarily recommended that the Genedrive® MT-RNR1 ID Kit can be used by the NHS
https://t.co/Qq7NG7Ovdi

[Ant Ryall @AntRyall]

#gdr

[genedrive plc @genedriveplc]

"Our experience of using this test has been very positive. Its straightforward, non-invasive and will have a huge impact on our patients' lives." National recognition for the Manchester-led product development 👏 ⬇️
#GDR #neonatal #pharmacogenetics https://t.co/7qsRFraOPG

[Ant Ryall @AntRyall]

#gdr

[genedrive plc @genedriveplc]

We are pleased to announce Connect Medizintechnik GmbH as our exclusive distribution partner in Austria for the Genedrive® MT-RNR1 product range. We look forward to working together to bring the benefits of bedside MT-RNR1 testing to Austria #GDR #hearingloss #neonatalcare

[Ant Ryall @AntRyall]

#gdr

[genedrive plc @genedriveplc]

Genedrive are pleased to announce Proyectos Hospitalarios Internacional, S.A. (PRHOINSA) @prhoinsa as our commercial partner in Spain for the Genedrive MT-RNR1 product range. We look forward to working together to bring the benefits of bedside MT-RNR1 testing to Spain #GDR

[Ant Ryall @AntRyall]

#gdr

[John McDermott @John_H_McD]

The PALOH study developed and implemented a rapid genetic test to avoid hearing loss in unwell babies.

This was a huge collaborative effort between @MFT_SaintMarys, @genedriveplc, & @EGS_UoM.

🏆 Last night our team were awarded the @NewStatesman Healthcare Impact Award.

1/4

[John McDermott @John_H_McD]

The PALOH study developed and implemented a rapid genetic test to avoid hearing loss in unwell babies.

This was a huge collaborative effort between @MFT_SaintMarys, @genedriveplc, & @EGS_UoM.

🏆 Last night our team were awarded the @NewStatesman Healthcare Impact Award.

1/4

[Ant Ryall @AntRyall]

#obd

[Ant Ryall @AntRyall]

#obd

[Ant Ryall @AntRyall]

#gdr

[genedrive plc @genedriveplc]

NICE initiated the new fast track process to drive #innovation into the hands of health and care professionals to enable best practice by providing a quicker assessment of products. The Genedrive MT-RNR1 assay is the only #molecular test being evaluated #GDR #POCT

[Ant Ryall @AntRyall]

#obd

[Ant Ryall @AntRyall]

#OBD

[Ant Ryall @AntRyall]

#obd

[Ant Ryall @AntRyall]

#obd wow

[Ant Ryall @AntRyall]

#gdr

[genedrive plc @genedriveplc]

Rapid genetic test could become new standard of care for #stroke

#GDR #pharmacogenetics #clopidogrel #POCT

https://t.co/wPBC7DfpCD

[Ant Ryall @AntRyall]

#GDR

[genedrive plc @genedriveplc]

📢A pre-sub has been filed to the US FDA to progress the regulatory approval for Genedrive® MT-RNR1 product range for the US market #GDR #neonatal #hearingloss #PGx #pharmacogenetics #antibiotics

🔗https://t.co/E0gwuzNZcw

[Ant Ryall @AntRyall]

#obd

[Ant Ryall @AntRyall]

#OBD

[Ant Ryall @AntRyall]

#obd